HighTower Advisors LLC Takes $430,000 Position in 10x Genomics, Inc. (NASDAQ:TXG)

HighTower Advisors LLC purchased a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 19,100 shares of the company’s stock, valued at approximately $430,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC lifted its stake in shares of 10x Genomics by 134.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company’s stock worth $32,000 after acquiring an additional 939 shares in the last quarter. ARK Investment Management LLC raised its position in shares of 10x Genomics by 48.2% in the 2nd quarter. ARK Investment Management LLC now owns 9,313,763 shares of the company’s stock valued at $181,153,000 after purchasing an additional 3,029,951 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of 10x Genomics by 19.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,971 shares of the company’s stock valued at $427,000 after buying an additional 3,603 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in shares of 10x Genomics during the second quarter worth approximately $216,000. Finally, CIBC Asset Management Inc grew its position in shares of 10x Genomics by 32.0% during the second quarter. CIBC Asset Management Inc now owns 95,259 shares of the company’s stock worth $1,853,000 after buying an additional 23,112 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

10x Genomics stock opened at $14.04 on Friday. 10x Genomics, Inc. has a twelve month low of $12.95 and a twelve month high of $57.78. The firm has a market cap of $1.70 billion, a PE ratio of -9.18 and a beta of 1.84. The firm’s 50 day moving average price is $15.29 and its two-hundred day moving average price is $18.71.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. The firm had revenue of $151.65 million for the quarter, compared to analyst estimates of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.51) earnings per share. Equities analysts anticipate that 10x Genomics, Inc. will post -1.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TXG has been the topic of several research analyst reports. Barclays reduced their price target on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. UBS Group reduced their target price on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. JPMorgan Chase & Co. lowered their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, October 30th. Leerink Partners began coverage on 10x Genomics in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $35.00 price target on the stock. Finally, Stephens reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of 10x Genomics in a report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, 10x Genomics presently has a consensus rating of “Moderate Buy” and an average price target of $25.14.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.